The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Identifieur interne : 002285 ( PubMed/Curation ); précédent : 002284; suivant : 002286The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Auteurs : Pei-Liang Wang [République populaire de Chine] ; Yong-Bo Cheng ; Gulina KuerbanSource :
- Journal of radiation research [ 1349-9157 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (), Adénocarcinome (radiothérapie), Adénocarcinome (sang), Adénocarcinome (traitement médicamenteux), Antinéoplasiques alcoylants (administration et posologie), Antinéoplasiques alcoylants (usage thérapeutique), Bléomycine (administration et posologie), Carcinome épidermoïde (), Carcinome épidermoïde (radiothérapie), Carcinome épidermoïde (sang), Carcinome épidermoïde (traitement médicamenteux), Chimioradiothérapie (effets indésirables), Chine (épidémiologie), Cisplatine (administration et posologie), Cisplatine (usage thérapeutique), Curiethérapie (effets indésirables), Femelle, Fluorouracil (administration et posologie), Groupes ethniques (), Humains, Hémoglobines (analyse), Ifosfamide (administration et posologie), Jambe, Lymphoedème (ethnologie), Lymphoedème (sang), Lymphoedème (étiologie), Numération des plaquettes, Oedème (ethnologie), Oedème (sang), Oedème (étiologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Radiothérapie de haute énergie (effets indésirables), Stade de la tumeur, Sujet âgé, Thrombophilie (sang), Thrombophilie (étiologie), Thrombose (), Thrombose (ethnologie), Thrombose (étiologie), Tumeurs du col de l'utérus (), Tumeurs du col de l'utérus (radiothérapie), Tumeurs du col de l'utérus (sang), Tumeurs du col de l'utérus (traitement médicamenteux), Vincristine (administration et posologie), Études rétrospectives.
- MESH :
- administration et posologie : Antinéoplasiques alcoylants, Bléomycine, Cisplatine, Fluorouracil, Ifosfamide, Vincristine.
- analyse : Hémoglobines.
- effets indésirables : Chimioradiothérapie, Curiethérapie, Radiothérapie de haute énergie.
- ethnologie : Lymphoedème, Oedème, Thrombose.
- radiothérapie : Adénocarcinome, Carcinome épidermoïde, Tumeurs du col de l'utérus.
- sang : Adénocarcinome, Carcinome épidermoïde, Lymphoedème, Oedème, Thrombophilie, Tumeurs du col de l'utérus.
- traitement médicamenteux : Adénocarcinome, Carcinome épidermoïde, Tumeurs du col de l'utérus.
- usage thérapeutique : Antinéoplasiques alcoylants, Cisplatine, Protocoles de polychimiothérapie antinéoplasique.
- épidémiologie : Chine.
- étiologie : Lymphoedème, Oedème, Thrombophilie, Thrombose.
- Adulte, Adulte d'âge moyen, Adénocarcinome, Carcinome épidermoïde, Femelle, Groupes ethniques, Humains, Jambe, Numération des plaquettes, Stade de la tumeur, Sujet âgé, Thrombose, Tumeurs du col de l'utérus, Études rétrospectives.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Adenocarcinoma (blood), Adenocarcinoma (complications), Adenocarcinoma (drug therapy), Adenocarcinoma (radiotherapy), Adult, Aged, Antineoplastic Agents, Alkylating (administration & dosage), Antineoplastic Agents, Alkylating (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bleomycin (administration & dosage), Brachytherapy (adverse effects), Carcinoma, Squamous Cell (blood), Carcinoma, Squamous Cell (complications), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (radiotherapy), Chemoradiotherapy (adverse effects), China (epidemiology), Cisplatin (administration & dosage), Cisplatin (therapeutic use), Edema (blood), Edema (ethnology), Edema (etiology), Ethnic Groups (statistics & numerical data), Female, Fluorouracil (administration & dosage), Hemoglobins (analysis), Humans, Ifosfamide (administration & dosage), Leg, Lymphedema (blood), Lymphedema (ethnology), Lymphedema (etiology), Middle Aged, Neoplasm Staging, Platelet Count, Radiotherapy, High-Energy (adverse effects), Retrospective Studies, Thrombophilia (blood), Thrombophilia (etiology), Thrombosis (complications), Thrombosis (ethnology), Thrombosis (etiology), Uterine Cervical Neoplasms (blood), Uterine Cervical Neoplasms (complications), Uterine Cervical Neoplasms (drug therapy), Uterine Cervical Neoplasms (radiotherapy), Vincristine (administration & dosage).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Alkylating, Bleomycin, Cisplatin, Fluorouracil, Ifosfamide, Vincristine.
- chemical , analysis : Hemoglobins.
- geographic , epidemiology : China.
- adverse effects : Brachytherapy, Chemoradiotherapy, Radiotherapy, High-Energy.
- blood : Adenocarcinoma, Carcinoma, Squamous Cell, Edema, Lymphedema, Thrombophilia, Uterine Cervical Neoplasms.
- complications : Adenocarcinoma, Carcinoma, Squamous Cell, Thrombosis, Uterine Cervical Neoplasms.
- drug therapy : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- ethnology : Edema, Lymphedema, Thrombosis.
- etiology : Edema, Lymphedema, Thrombophilia, Thrombosis.
- radiotherapy : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- statistics & numerical data : Ethnic Groups.
- chemical , therapeutic use : Antineoplastic Agents, Alkylating, Antineoplastic Combined Chemotherapy Protocols, Cisplatin.
- Adult, Aged, Female, Humans, Leg, Middle Aged, Neoplasm Staging, Platelet Count, Retrospective Studies.
Abstract
Thrombosis-related edema and lymphedema are two principal types of lower extremity edema results from radiotherapy alone or chemoradiotherapy for patients with cervical cancer. To characterize differences between them, a retrospective study was performed. We collected data including age, race, body weight, FIGO stage, histology type, platelet count, haemoglobin, time of definitely diagnosis, therapeutic regimen, edema type and which leg edema firstly occurred in. Of 40 patients who were eligible for this study, 32 were diagnosed as thrombosis-related edema and 8 diagnosed as lymphedema. The differences in patient age (p = 0.004), propotion of race (p = 0.021), the latent time (p = 0.002) and the mean platelet count (p = 0.019) were statistically significant. Among 32 patients with thrombosis-related edema, 34.4% were in stage II and 53.1% in stage III, 78.1% were squamous cell carcinoma. Among 8 patients with lymphedema, 87.5% were in stage II and 62.5% were squamous cell carcinoma. The differences were not statistically significant for weight (p = 0.94), histology type (p = 0.648), edema site (p = 0.236), haemoglobin (p = 0.088) between the two grouping patients. Although the small patient cohort is a limitation, the results suggest that the patients with thrombosis-related edema may have higher proportion, lower age, shorter latent edema time and more platelet count than those with lymphedema. Also, thrombosis-related edema was likely inclined to Uigur and lymphedema to Han race. We did not find statistical differences in weight, edema site, histology type and haemoglobin between patients with thrombosis-related edema and lymphedema.
PubMed: 22302053
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002285
Links to Exploration step
pubmed:22302053Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.</title>
<author><name sortKey="Wang, Pei Liang" sort="Wang, Pei Liang" uniqKey="Wang P" first="Pei-Liang" last="Wang">Pei-Liang Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. wp1123456@126.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cheng, Yong Bo" sort="Cheng, Yong Bo" uniqKey="Cheng Y" first="Yong-Bo" last="Cheng">Yong-Bo Cheng</name>
</author>
<author><name sortKey="Kuerban, Gulina" sort="Kuerban, Gulina" uniqKey="Kuerban G" first="Gulina" last="Kuerban">Gulina Kuerban</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22302053</idno>
<idno type="pmid">22302053</idno>
<idno type="wicri:Area/PubMed/Corpus">002285</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002285</idno>
<idno type="wicri:Area/PubMed/Curation">002285</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002285</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.</title>
<author><name sortKey="Wang, Pei Liang" sort="Wang, Pei Liang" uniqKey="Wang P" first="Pei-Liang" last="Wang">Pei-Liang Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. wp1123456@126.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cheng, Yong Bo" sort="Cheng, Yong Bo" uniqKey="Cheng Y" first="Yong-Bo" last="Cheng">Yong-Bo Cheng</name>
</author>
<author><name sortKey="Kuerban, Gulina" sort="Kuerban, Gulina" uniqKey="Kuerban G" first="Gulina" last="Kuerban">Gulina Kuerban</name>
</author>
</analytic>
<series><title level="j">Journal of radiation research</title>
<idno type="eISSN">1349-9157</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (blood)</term>
<term>Adenocarcinoma (complications)</term>
<term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (radiotherapy)</term>
<term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents, Alkylating (administration & dosage)</term>
<term>Antineoplastic Agents, Alkylating (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bleomycin (administration & dosage)</term>
<term>Brachytherapy (adverse effects)</term>
<term>Carcinoma, Squamous Cell (blood)</term>
<term>Carcinoma, Squamous Cell (complications)</term>
<term>Carcinoma, Squamous Cell (drug therapy)</term>
<term>Carcinoma, Squamous Cell (radiotherapy)</term>
<term>Chemoradiotherapy (adverse effects)</term>
<term>China (epidemiology)</term>
<term>Cisplatin (administration & dosage)</term>
<term>Cisplatin (therapeutic use)</term>
<term>Edema (blood)</term>
<term>Edema (ethnology)</term>
<term>Edema (etiology)</term>
<term>Ethnic Groups (statistics & numerical data)</term>
<term>Female</term>
<term>Fluorouracil (administration & dosage)</term>
<term>Hemoglobins (analysis)</term>
<term>Humans</term>
<term>Ifosfamide (administration & dosage)</term>
<term>Leg</term>
<term>Lymphedema (blood)</term>
<term>Lymphedema (ethnology)</term>
<term>Lymphedema (etiology)</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Platelet Count</term>
<term>Radiotherapy, High-Energy (adverse effects)</term>
<term>Retrospective Studies</term>
<term>Thrombophilia (blood)</term>
<term>Thrombophilia (etiology)</term>
<term>Thrombosis (complications)</term>
<term>Thrombosis (ethnology)</term>
<term>Thrombosis (etiology)</term>
<term>Uterine Cervical Neoplasms (blood)</term>
<term>Uterine Cervical Neoplasms (complications)</term>
<term>Uterine Cervical Neoplasms (drug therapy)</term>
<term>Uterine Cervical Neoplasms (radiotherapy)</term>
<term>Vincristine (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Adénocarcinome ()</term>
<term>Adénocarcinome (radiothérapie)</term>
<term>Adénocarcinome (sang)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Antinéoplasiques alcoylants (administration et posologie)</term>
<term>Antinéoplasiques alcoylants (usage thérapeutique)</term>
<term>Bléomycine (administration et posologie)</term>
<term>Carcinome épidermoïde ()</term>
<term>Carcinome épidermoïde (radiothérapie)</term>
<term>Carcinome épidermoïde (sang)</term>
<term>Carcinome épidermoïde (traitement médicamenteux)</term>
<term>Chimioradiothérapie (effets indésirables)</term>
<term>Chine (épidémiologie)</term>
<term>Cisplatine (administration et posologie)</term>
<term>Cisplatine (usage thérapeutique)</term>
<term>Curiethérapie (effets indésirables)</term>
<term>Femelle</term>
<term>Fluorouracil (administration et posologie)</term>
<term>Groupes ethniques ()</term>
<term>Humains</term>
<term>Hémoglobines (analyse)</term>
<term>Ifosfamide (administration et posologie)</term>
<term>Jambe</term>
<term>Lymphoedème (ethnologie)</term>
<term>Lymphoedème (sang)</term>
<term>Lymphoedème (étiologie)</term>
<term>Numération des plaquettes</term>
<term>Oedème (ethnologie)</term>
<term>Oedème (sang)</term>
<term>Oedème (étiologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Radiothérapie de haute énergie (effets indésirables)</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Thrombophilie (sang)</term>
<term>Thrombophilie (étiologie)</term>
<term>Thrombose ()</term>
<term>Thrombose (ethnologie)</term>
<term>Thrombose (étiologie)</term>
<term>Tumeurs du col de l'utérus ()</term>
<term>Tumeurs du col de l'utérus (radiothérapie)</term>
<term>Tumeurs du col de l'utérus (sang)</term>
<term>Tumeurs du col de l'utérus (traitement médicamenteux)</term>
<term>Vincristine (administration et posologie)</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Alkylating</term>
<term>Bleomycin</term>
<term>Cisplatin</term>
<term>Fluorouracil</term>
<term>Ifosfamide</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Hemoglobins</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques alcoylants</term>
<term>Bléomycine</term>
<term>Cisplatine</term>
<term>Fluorouracil</term>
<term>Ifosfamide</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Brachytherapy</term>
<term>Chemoradiotherapy</term>
<term>Radiotherapy, High-Energy</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hémoglobines</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Edema</term>
<term>Lymphedema</term>
<term>Thrombophilia</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Thrombosis</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Chimioradiothérapie</term>
<term>Curiethérapie</term>
<term>Radiothérapie de haute énergie</term>
</keywords>
<keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Lymphoedème</term>
<term>Oedème</term>
<term>Thrombose</term>
</keywords>
<keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Edema</term>
<term>Lymphedema</term>
<term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Edema</term>
<term>Lymphedema</term>
<term>Thrombophilia</term>
<term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Lymphoedème</term>
<term>Oedème</term>
<term>Thrombophilie</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Ethnic Groups</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents, Alkylating</term>
<term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Cisplatin</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques alcoylants</term>
<term>Cisplatine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Chine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term>
<term>Oedème</term>
<term>Thrombophilie</term>
<term>Thrombose</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Leg</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Platelet Count</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Femelle</term>
<term>Groupes ethniques</term>
<term>Humains</term>
<term>Jambe</term>
<term>Numération des plaquettes</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Thrombose</term>
<term>Tumeurs du col de l'utérus</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Thrombosis-related edema and lymphedema are two principal types of lower extremity edema results from radiotherapy alone or chemoradiotherapy for patients with cervical cancer. To characterize differences between them, a retrospective study was performed. We collected data including age, race, body weight, FIGO stage, histology type, platelet count, haemoglobin, time of definitely diagnosis, therapeutic regimen, edema type and which leg edema firstly occurred in. Of 40 patients who were eligible for this study, 32 were diagnosed as thrombosis-related edema and 8 diagnosed as lymphedema. The differences in patient age (p = 0.004), propotion of race (p = 0.021), the latent time (p = 0.002) and the mean platelet count (p = 0.019) were statistically significant. Among 32 patients with thrombosis-related edema, 34.4% were in stage II and 53.1% in stage III, 78.1% were squamous cell carcinoma. Among 8 patients with lymphedema, 87.5% were in stage II and 62.5% were squamous cell carcinoma. The differences were not statistically significant for weight (p = 0.94), histology type (p = 0.648), edema site (p = 0.236), haemoglobin (p = 0.088) between the two grouping patients. Although the small patient cohort is a limitation, the results suggest that the patients with thrombosis-related edema may have higher proportion, lower age, shorter latent edema time and more platelet count than those with lymphedema. Also, thrombosis-related edema was likely inclined to Uigur and lymphedema to Han race. We did not find statistical differences in weight, edema site, histology type and haemoglobin between patients with thrombosis-related edema and lymphedema.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22302053</PMID>
<DateCreated><Year>2012</Year>
<Month>02</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>06</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1349-9157</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>53</Volume>
<Issue>1</Issue>
<PubDate><Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>Journal of radiation research</Title>
<ISOAbbreviation>J. Radiat. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.</ArticleTitle>
<Pagination><MedlinePgn>125-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Thrombosis-related edema and lymphedema are two principal types of lower extremity edema results from radiotherapy alone or chemoradiotherapy for patients with cervical cancer. To characterize differences between them, a retrospective study was performed. We collected data including age, race, body weight, FIGO stage, histology type, platelet count, haemoglobin, time of definitely diagnosis, therapeutic regimen, edema type and which leg edema firstly occurred in. Of 40 patients who were eligible for this study, 32 were diagnosed as thrombosis-related edema and 8 diagnosed as lymphedema. The differences in patient age (p = 0.004), propotion of race (p = 0.021), the latent time (p = 0.002) and the mean platelet count (p = 0.019) were statistically significant. Among 32 patients with thrombosis-related edema, 34.4% were in stage II and 53.1% in stage III, 78.1% were squamous cell carcinoma. Among 8 patients with lymphedema, 87.5% were in stage II and 62.5% were squamous cell carcinoma. The differences were not statistically significant for weight (p = 0.94), histology type (p = 0.648), edema site (p = 0.236), haemoglobin (p = 0.088) between the two grouping patients. Although the small patient cohort is a limitation, the results suggest that the patients with thrombosis-related edema may have higher proportion, lower age, shorter latent edema time and more platelet count than those with lymphedema. Also, thrombosis-related edema was likely inclined to Uigur and lymphedema to Han race. We did not find statistical differences in weight, edema site, histology type and haemoglobin between patients with thrombosis-related edema and lymphedema.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Pei-Liang</ForeName>
<Initials>PL</Initials>
<AffiliationInfo><Affiliation>Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. wp1123456@126.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Yong-Bo</ForeName>
<Initials>YB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuerban</LastName>
<ForeName>Gulina</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Radiat Res</MedlineTA>
<NlmUniqueID>0376611</NlmUniqueID>
<ISSNLinking>0449-3060</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>11056-06-7</RegistryNumber>
<NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>UM20QQM95Y</RegistryNumber>
<NameOfSubstance UI="D007069">Ifosfamide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018906" MajorTopicYN="N">Antineoplastic Agents, Alkylating</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001761" MajorTopicYN="N">Bleomycin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001918" MajorTopicYN="N">Brachytherapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007069" MajorTopicYN="N">Ifosfamide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011882" MajorTopicYN="N">Radiotherapy, High-Energy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>6</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22302053</ArticleId>
<ArticleId IdType="pii">JST.JSTAGE/jrr/11094</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:22302053 |texte= The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22302053" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |